Glaukos (GKOS) Competitors $96.54 +1.42 (+1.49%) Closing price 03:59 PM EasternExtended Trading$96.56 +0.02 (+0.02%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GKOS vs. SNN, SOLV, PEN, STVN, IRTC, BLCO, TMDX, SLNO, NVST, and LIVNShould you be buying Glaukos stock or one of its competitors? The main competitors of Glaukos include Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry. Glaukos vs. Its Competitors Smith & Nephew SNATS Solventum Penumbra Stevanato Group iRhythm Technologies Bausch + Lomb TransMedics Group Soleno Therapeutics Envista LivaNova Glaukos (NYSE:GKOS) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation. Is GKOS or SNN more profitable? Smith & Nephew SNATS has a net margin of 0.00% compared to Glaukos' net margin of -21.43%. Smith & Nephew SNATS's return on equity of 0.00% beat Glaukos' return on equity.Company Net Margins Return on Equity Return on Assets Glaukos-21.43% -8.59% -6.61% Smith & Nephew SNATS N/A N/A N/A Do analysts prefer GKOS or SNN? Glaukos presently has a consensus price target of $127.42, indicating a potential upside of 31.98%. Smith & Nephew SNATS has a consensus price target of $36.00, indicating a potential downside of 3.42%. Given Glaukos' stronger consensus rating and higher possible upside, analysts clearly believe Glaukos is more favorable than Smith & Nephew SNATS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Glaukos 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.79Smith & Nephew SNATS 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger earnings & valuation, GKOS or SNN? Smith & Nephew SNATS has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Smith & Nephew SNATS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlaukos$383.48M14.44-$146.37M-$1.65-58.51Smith & Nephew SNATS$5.81B2.81$412M$2.1617.26 Does the media favor GKOS or SNN? In the previous week, Glaukos had 7 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 18 mentions for Glaukos and 11 mentions for Smith & Nephew SNATS. Glaukos' average media sentiment score of 0.98 beat Smith & Nephew SNATS's score of 0.89 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, GKOS or SNN? Glaukos has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Smith & Nephew SNATS has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Do insiders and institutionals hold more shares of GKOS or SNN? 99.0% of Glaukos shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 5.8% of Glaukos shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryGlaukos beats Smith & Nephew SNATS on 10 of the 17 factors compared between the two stocks. Get Glaukos News Delivered to You Automatically Sign up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GKOS vs. The Competition Export to ExcelMetricGlaukosMED INSTRUMENTS IndustryMedical SectorNYSE ExchangeMarket Cap$5.54B$6.94B$5.76B$21.29BDividend YieldN/A1.30%3.95%3.53%P/E Ratio-58.5126.3631.3129.36Price / Sales14.4456.55461.5774.71Price / CashN/A21.6137.7623.64Price / Book7.246.9110.025.38Net Income-$146.37M$176.42M$3.27B$996.59M7 Day Performance7.47%3.69%3.17%3.12%1 Month Performance1.84%-1.34%4.34%2.97%1 Year Performance-28.69%10.18%44.12%12.83% Glaukos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GKOSGlaukos4.7292 of 5 stars$96.54+1.5%$127.42+32.0%-29.5%$5.54B$383.48M-58.51780Analyst RevisionSNNSmith & Nephew SNATS2.9685 of 5 stars$37.20-0.8%$36.00-3.2%+19.6%$16.29B$5.81B17.2217,349Positive NewsSOLVSolventum1.5107 of 5 stars$72.82-1.0%$85.75+17.8%+20.5%$12.63B$8.39B33.7122,000Positive NewsPENPenumbra4.7878 of 5 stars$265.19+0.2%$300.47+13.3%+31.9%$10.34B$1.19B70.534,500STVNStevanato Group1.7874 of 5 stars€21.99-2.8%N/A+9.2%€6.66B€1.19B40.725,521News CoveragePositive NewsIRTCiRhythm Technologies1.317 of 5 stars$165.68-2.0%$162.64-1.8%+149.9%$5.32B$657.23M-56.552,000Analyst ForecastBLCOBausch + Lomb1.1758 of 5 stars$14.57-2.5%$15.56+6.8%-10.2%$5.16B$4.79B-18.6713,500TMDXTransMedics Group2.8958 of 5 stars$114.97-4.1%$123.00+7.0%-33.3%$3.92B$441.54M59.57210Positive NewsAnalyst ForecastSLNOSoleno Therapeutics4.5612 of 5 stars$66.51-3.0%$115.09+73.0%+38.0%$3.53B$32.66M-16.0730News CoverageAnalyst ForecastNVSTEnvista3.6014 of 5 stars$21.15-2.6%$20.92-1.1%+13.6%$3.51B$2.51B66.1012,300LIVNLivaNova1.6164 of 5 stars$56.35+0.8%$59.71+6.0%+21.2%$3.05B$1.31B-14.492,900Positive News Related Companies and Tools Related Companies SNN Alternatives SOLV Alternatives PEN Alternatives STVN Alternatives IRTC Alternatives BLCO Alternatives TMDX Alternatives SLNO Alternatives NVST Alternatives LIVN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:GKOS) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredSell this, buy thatI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Glaukos Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Glaukos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access